MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

Is Bristol Myers Squibb's New Multiple Myeloma Drug a Game Changer

4 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is Bristol Myers Squibb's Deucravacitinib a Game-Changer for SLE Patients and BMY Investors

2 months ago

Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now

4 months ago

Why Are Barclays Analysts Bullish on Eli Lilly and Bristol-Myers Squibb

4 months ago

Why Are UnitedHealth Group and Bristol-Myers Squibb Attracting Hedge Funds

1 months ago

3 Reasons to Buy Bristol Myers Squibb Stock

Bristol Myers Squibb faces a large revenue gap but appears positioned to address it, supported by a robust dividend yield that compensates investors during the transition.

BMY

Stock News•1 months ago

Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Bristol-Myers Squibb (BMY) presented at the Goldman Sachs 47th Annual Global Healthcare Conference 2026. The presentation covered the company's strategic outlook and pipeline updates.

BMY

Stock News•1 months ago

Bristol Myers drug delays myeloma progression in hard to treat patients

Bristol Myers Squibb’s experimental oral drug mezigdomide delayed disease progression in a late-stage trial for patients with relapsed or refractory multiple myeloma. The results suggest a potential n...

BMY

News•1 months ago

The Cancer Test That Wall Street Is Betting On

A diagnostic company has established an early market lead in blood-based cancer recurrence testing. This technology aims to detect returning cancer in survivors, positioning the firm as a potential le...